The large-scale and cost-effective production of quality-controlled human pluripotent stem cells (hPSC) for 13 use in cell therapy and drug discovery requires chemically-defined xenobiotic-free culture systems that 14 enable easy and homogeneous expansion of pluripotent cells. Through phenotypic screening, we have 15 identified a small molecule, OXS8360 (an optimized derivative of (-)-Indolactam V ((-)-ILV)), that 16 stably disrupts hPSC cell-cell contacts. Proliferation of hPSC in OXS8360 is normal, as are 17 pluripotency signatures, directed differentiation to hallmark lineages and karyotype over extended 18 passaging. In 3D culture, OXS8360-treated hPSC form smaller, more uniform aggregates, that are 19 easier to dissociate, greatly facilitating expansion. The mode of action of OXS8360 involves 20 disruption of the localisation of the cell-cell adhesion molecule E-cadherin, via activation of 21 unconventional Protein Kinase C isoforms. OXS8360 media supplementation is therefore able to 22 yield more uniform, disaggregated 2D and 3D hPSC cultures, providing the hPSC field with an 23 affordable tool to improve hPSC quality and scalability. 24 25
cells of consistent quality and in a cost effective manner. In addition, the application of hPSC also requires 30 ease of use, and good manufacturing practice (GMP) compatibility, without compromising pluripotency or 31 increasing heterogeneity in the culture 2 . While hPSC are most commonly grown in chemically defined media, 32 such as mTeSR1 TM 3 or E8 4 , the main challenge encountered in traditional 2D culture methods is the limited 33 quantities in which hPSC can be produced for experimental and therapeutic application. Zweigerdt et al. 5 34 have shown that at least 2x10 9 differentiated cells of the representative lineage would be necessary to treat 35 one individual in the case of heart repair or β-cell replacement in type 1 diabetes, which requires about 500 36 densely grown 10-cm dishes and complex automation. One strategy for overcoming these difficulties is to 37 develop 3D suspension culture methods allowing more reliable, simple, cost-effective and industrial-scale 38 production of hPSC versus 2D systems. Free-floating 3D cultures (e.g. suspension culture in bioreactors) are 39 expected to meet the high demand for cells needed for such applications. However, this approach can invoke 40 problems with cell aggregation. Cells in the centre of these aggregates are generally underexposed to the 41 medium, resulting in variable growth rates, apoptosis, uncontrolled differentiation and an eventual increase 42 in heterogeneity 6 . Others have also explored the use of mechanical agitation (limited by shearing force), 43 microcarriers, micropatterning and thermoreversible hydrogels 7, 8 . Despite their contribution to the field, 44 each has its own limitations and struggle either to support rapid expansion or to prevent the formation of 45 heterogeneous cell aggregates, leading to loss of pluripotency at higher cell densities 2, 8 . Chemical approaches 46 to disrupt cell-cell contact in hPSC while maintaining pluripotency are an innovative approach to address this 47 line 11 in the first instance (Table S1 ). This identified the natural compound (-)-ILV ( Fig. 1a) , which allowed cells 57 to separate from their neighbours in a concentration-dependent manner, with a minimal effective 58 concentration of 1 µM (Fig. 1b ). However, as (-)-ILV exhibited a reduction in cell viability over time (Fig. S1) , 59 an analysis of structural analogues of (-)-ILV was undertaken. One analogue, OXS8360 (Fig. 1a) , induced iPSC 60 cell scattering at 1 µM while maintaining high viability, as assessed by acridine orange. iPSC were cultured in 61 the presence of (-)-ILV or OXS8360 and imaged after 3, 12 and 24h of treatment ( Fig. 1b ). Morphological 62 changes were observable within 3h post treatment, with particularly pronounced separation of cells on 63 colony peripheries, indicating the rapid effect of OXS8360. Colony disruption was more evident at 12h and 64 reached a completely non-colony-based phenotype by 24h. Live imaging of OX8360-treated iPSC also showed 65 a dynamically spreading phenotypic effect over 5 hours versus untreated cells (Video, S.I). Additionally, three 66 genetically distinct healthy control donor iPSC lines (SFC840-03-06, SFC85403-02, and SFC856-03-04 12 ) ( Table  67 S1) treated with either (-)-ILV or OXS8360 showed the same phenotypic effect, demonstrating the robustness 68 of the effect (Fig. S2 ). Finally, the karyotypes of all four iPS cell lines remained stable over 10 passages of 69 OXS8360-treatment ( Fig. S3 ). 70
Next, the reversibility of (-)-ILV and OXS8360-induced morphological changes was assessed (experimental 71 timeline schematically presented in Fig. 1c ). 24h after plating (in medium containing Rho-kinase inhibitor 72 Y27632 to prevent apoptosis during single cell passaging), iPSC started to form early colonies. Removal of 73 Rho-kinase inhibitor and subsequent treatment with 1μM (-)-ILV or OXS8360 showed colony disruption 24h 74 later. Finally, colony-based morphology was restored 24h after a compound-free medium change ( Fig. 1c ). 75
As (-)-ILV or OXS8360 treatment induced iPSC scattering, the resultant changes in cell morphology were 76 quantified. Treatment with (-)-ILV or OXS8360 induced a significant reduction in cell density (nuclei/area) 77 versus DMSO (3.5-fold and 2.7-fold, respectively). This was accompanied by a flattening of the phenotype, 78 resulting in nuclei that were significantly greater in area and perimeter but significantly reduced in height 79 ( Fig. 1d ). Geometric mean forward scatter (which reflects cell volume, obtained from flow cytometry 80 datasets) showed no significant difference between OXS8360-treated and untreated iPSC (by comparison, 81 human dermal fibroblasts (HDF) were significantly higher, Fig.1d) , showing that overall cell volume was not 82 changed, just a transition to a more flattened phenotype. Staining of iPSC actin filaments with phalloidin-83 iFluor 488 revealed cytoskeleton remodelling upon (-)-ILV or OXS8360 treatment. Control iPSC were 84 characterized by few but organized actin filaments at cell-cell contacts, whereas (-)-ILV or OXS8360-treated 85 iPSC had a significant increase (5.8 and 3.5 fold, respectively) in phalloidin signal, with F-actin arranged as 86 stress fibres, indicative of weak cell-cell junctions 13, 14 ( Fig. 1d and 1e ). These results show that both (-)-ILV 87 and OXS8360 induce colony disruption involving substantial actin rearrangement in 2D-cultured iPSC, and 88 that this phenotype is reversible. 89 90 iPSC proliferate normally with OXS8360. 91
As we had noted that (-)-ILV was toxic to iPSC, we explored the mechanism of cell death, and determined the 92 concentration that inhibits cell survival by 50% for each compound. Activity assays for caspase 3 and 7 in 93 whole cell lysates from iPSC treated over 24 h with concentrations ranging from 0.1 to 100 µM showed that 94 (-)-ILV induced caspase 3 and 7 activation in a dose-dependent manner, with half maximal activity at 0.33 95 µM ( Fig. S4 ). Half maximal activity for OXS8360-treated cells was at 89.1 µM, indicating much lower caspase 96 induction. Flow cytometry for Annexin V-FITC and Propidium Iodide of (-)-ILV-treated cells showed that over 97 72h they shifted progressively from a population of healthy cells (Q4) to early apoptotic (Q3) and late 98 apoptotic populations (Q2) ( Fig. S5 ). These findings show that (-)-ILV exhibits high toxicity towards iPSC, 99 therefore (-)-ILV was not used further, and only OXS8360 was taken forward for further studies. 100
To test whether iPSC proliferative ability would be affected following OXS8360 treatment, we examined 101 expression of Ki-67, a protein that is present during all active phases of the cell cycle (G(1), S, G(2), and 102 mitosis), but is absent from resting cells (G(0)) 15 . Confocal imaging of untreated and OXS8360-treated iPSC 103 for three passages revealed high levels of Ki-67 staining in both conditions (with HDF serving as a low-104 proliferating control) ( Fig. 2a ). Flow cytometry quantification of Ki-67-positive cells showed no significant 105 difference between OXS8360 treated iPSC (99.4%±0.05; n=3), versus controls (99.0%±0.12; n=3), with HDF 106 (12.3%±0.03, n=3) significantly lower than iPSC ( Fig. 2b, 2c) . 107 108
OXS8360-treated iPSC maintain pluripotent signatures. 109
We next examined whether OXS8360 had any effect on the pluripotency signatures of iPSC treated over 110 multiple passages. Firstly, untreated cells or cells treated for 3 passages were similarly Nanog + /Tra-1-111 60 + /SSEA-3 + /SSEA-4 + by flow cytometry (Fig. 3a) , and negative for the mesenchymal surface marker CD44 16 . 112
Furthermore, immunocytochemical analysis of cells confirmed Tra-1-60 and Nanog expression ( Fig. 3b ). iPSC 113 treated with OXS8360 over 10 passages continued to express Tra-1-60 and Nanog, more consistently than 114 the untreated controls, in all four genetically distinct cell lines ( Fig. S6 ). Therefore, the expression of 115 pluripotency markers in iPSC cultured with 1µM OXS8360 is stable over at least 10 passages. 116 117 Gene expression signatures can effectively report on the differentiation potential of hPSCs 17 , and ScoreCard, 118 a qRT-PCR-based assay that evaluates pluripotency and differentiation signatures, offers a valuable 119 quantitative approach for line-to-line comparison. Moreover, ScoreCard has been shown to be sensitive 120 enough to compare the functional pluripotency of samples in distinct culture conditions, making it an 121 appropriate genetic tool for our purpose 18 . Hence, Scorecard was used to test iPSC treated for three passages 122 with OXS8360, to assess self-renewal signatures and undirected differentiation to the three germline lineages 123 via embryoid bodies (EBs) 19, 20 (imaged in Fig. S7 ). Both control DMSO and OXS8360-treated iPSC displayed 124 expected expression signatures representing pluripotency, ectodermal, mesodermal and endodermal 125 differentiation ( Fig. 3c ), expressed in an algorithm score against a reference dataset ( Fig.3d ), with consistent 126 positive scores for pluripotency and negative scores for the three differentiation signatures as 127 undifferentiated cells, and upregulated gene signatures for all three germ layers upon spontaneous 128 differentiation ( Fig.3e , Ct values Table S2 ). 129 130 OXS8360-treated iPSC exhibit normal directed differentiation. 131 6 CD11b, CD14 and CD45 ( Fig. 4b ). Directed differentiation of iPSC treated for three passages with OXS8360 to 136 a neuroectodermal lineage (cortical neuron progenitors) 22 , gave rise to neuronal rosettes on day 16, followed 137 by neurons visible at day 25 ( Fig. 4c ), which expressed cortical neuron markers TUJ1 and PAX-6 ( Fig. 4d ). 138
Together, these results show that OXS8360-treated iPSC are competent at directed differentiation to key 139 mesodermal and neurectodermal lineages. 140
141

3D culture of iPSC with OXS8360 enables formation of smaller aggregates. 142
To assess whether the scattering of OXS8360-treated iPSC in 2D culture would lead to improved 3D culture, 143 iPSC were seeded in six-well low attachment plates at 0.5x10 6 cells per well (adapted from Zweigert et al. 5 ) 144 and cultured for 10 passages in suspension, subculturing every 4 days with or without OXS8360. 4 days after 145 the 10 th passage, untreated cells remained in large aggregates, whereas OXS8360 treated iPSC formed much 146 smaller aggregates ( Fig. 5a, Fig. S8 ). After 10 passages, Tra 1-60 and Nanog showed bimodal expression in 147 the untreated cells, indicating a population of non-pluripotent cells, whereas OXS8360-treated cells retained 148 a monomodal expression ( Fig. 5b ). Mean aggregate area was significantly smaller for OXS8360-treated (p < 149 0.001) versus untreated cultures ( Fig. 5c ). A three to six-fold expansion in seeded cells was observed during 150 each passage for both conditions (Fig. S9 ). OXS8360-treated aggregates were much more easily dissociated 151 to single cells as evidenced by significantly fewer residual cell clusters (14.5%±1.15, n=3, p<0.001) versus 152 control cultures (33%±1.15, n=3) ( Fig. 5d ). Finally, the karyotype of iPSC treated with OXS8360 for 10 passages 153 remained stable ( Fig S3) . These results show that iPSC can be 3D-cultured for extended periods of time in 154 OXS8360 containing medium, reducing aggregation, maintaining pluripotency and facilitating dissociation. 155
156
OXS8360 suppresses homophilic interactions between the extracellular domains of E-cadherin in iPSC. 157
To explore the effect of OXS8360 on iPSC architecture, specifically E-cadherin-associated adherens junctions, 158 OXS8360-treated iPSC were fixed and stained with anti E-cadherin mAb clones 36 and SHE78-7, commercially 159 available antibodies that recognise an intracellular portion and the first extracellular domain (EC1) of E-160 cadherin respectively 23, 24 . Fluorescence intensity remained similar between treated and control cells when 161 stained for intracellular E-cadherin ( Fig. 6a ). In contrast, and consistent with the observed disruption of iPSC 7 colonies, the fluorescence intensity at cell-cell contacts revealed using the EC1 antibody recognising the 163 extracellular domain was much weaker in OXS8360-treated cells than control cells. As OXS8360 has been reported to be a protein kinase C (PKC) activator, binding to the conventional (α, β, γ) 177 and novel (δ, ε) PKC isoforms 27 , we hypothesised that the observed iPSC phenotype may be mediated through 178 this pathway. A comparison with structurally unrelated PKC activators was first carried out. Treatment of 179 iPSC with commercially available phorbol esters (known to be PKC activators 28 ) gave a similar effect on colony 180 disruption to OXS8360 ( Fig. S10 ). We next determined the expression levels of PKC isoforms in iPSC, which 181 have been reported to exhibit tissue-specific levels of expression 28 All conventional, novel and atypical PKC 182 isoforms (cPKC, nPKC, aPKC) were expressed in the iPSC line OX1-18, with PKC δ, ι and ζ the most highly 183 expressed. With the exception of PKCδ, no significant differences in the expression of isoforms were observed 184 upon 72h treatment with OXS8360 compared with untreated cells (Fig. 6c ). 185
186
In addition, using a relative kinase assay, we observed that 1 µM OXS8360 induced a statistically significant 187 increase in PKC enzymatic activity in iPSC ( Fig. 6d ). 188
Finally, two pharmacological PKC inhibitors, namely Gö6976 and Gö6983, were tested for their ability to block 190 OXS8360-induced morphological change in iPSC. These inhibitors have been shown to inhibit PKC isoforms 191 at nanomolar concentrations 29, 30 . Gö6976 has been reported to be a specific inhibitor of the conventional 192 PKC isoforms α and β whereas Gö6983 acts as pan-PKC inhibitor with more affinity for conventional and novel 193 isoforms than atypical isoforms 29, 30 . While blocking the PKC pathway with conventional PKC inhibitor Gö6976 194 had no effect, pan-PKC inhibitor Gö6983 reversed the effect of OXS8360 on colony disruption (Fig. 6e) , 195
suggesting the effects of OXS8360 may be mediated via unconventional PKC isoforms. colonies. However, note that we could not confirm total contact-independence. OXS8360-treated 3D-208 cultured cells displayed smaller, looser aggregates, resulting in a more homogeneous cell population, with 209 improved dissociation capacity. This overcomes several limitations of current 3D aggregate systems, 210 especially transport of nutrients and small molecules that play an important role in pluripotency 211 maintenance 6, 32 . 212 213 OXS8360-treated iPSC maintained a highly proliferative self-renewal capacity 33 (assessed by Ki-67 staining 214 and cumulative cell-count), and a pluripotent signature, shown by expression of widely accepted markers 34 , 215 mesodermal (macrophages) and neurectodermal (cerebral cortical neurons) lineages. Extended culture for 217 10 passages demonstrated that OXS8360-treated iPSC preserved their key iPSC characteristics, including 218 karyotypic stability. Therefore, OXS8360 is fully compatible with iPSC functionality over extended passaging. 219 220 To elucidate the mechanism of action of OXS8360, and consistent with previous reports 27 , we showed that 221 OXS8360 increased PKC activity in iPSC. PKC is a pleiotropic enzyme, but also mediates the tumour-promoting 222 activity of phorbol esters and certain teleocidin natural products, including (-)-ILV 35 
Cell lines and culture 272
This study was carried out using four reprogrammed iPSC lines (Table S1) All experiments were performed in accordance with UK guidelines and regulations and as set out in the REC 278 and the iPSC lines used have all been published previously (Table S1) . For static suspension culture i , 6-well plates with repellant surfaces were used (Greiner Bio-One TM ). 3 mL of a 288 cell suspension at a density of 0.33x10 6 cells/mL were supplemented with 100 units/mL penicillin-289 streptomycin and 10 µM ROCK inhibitor Y-27632. Aggregates were allowed to form at 37°C in a humidified 290 atmosphere with 5% CO2 over 4 days with no medium change. On day 4 of suspension culture, aggregates 291 were transferred to 15-mL tubes. Supernatant was removed after centrifugation at 400 rcf for 5 min. This 292 was followed by incubation in 1 mL of TrypLE for 5 min in a water bath set at 37°C. Cells were centrifuged at 293 300 rcf for 4 min to remove the supernantant and resuspended in 1 mL of mTesR TM prior to filtration through 294 a 30 μm sieve. The membrane was washed with 1 mL mTeSR TM and cells were resuspended in the appropriate 295 volume of ROCK inhibitor Y-27632 supplemented mTeSR1 TM . A dedicated incubator was used to prevent 296 inadvertent agitation of the cultures through door opening/closing. 297
When treated with compounds for experiments, cells were cultured in the presence of 0.1% DMSO, 1 µM (-298 )-ILV, or 1 µM OXS8360 unless stated otherwise. Cell phenotype was monitored by using phase contrast 299 microscopy with an EVOS XL cell imaging system. 300
HDFs were cultured in T-25 flasks (Corning) at 37°C and 5% CO2 with 6 mL HDF medium consisting of 1x 301
Advanced DMEM (Gibco TM ), 1x Glutamax TM (Gibco TM ), 100 μM β-mercaptoethanol (Gibco TM ), 0.1x fetal 302 bovine serum (Sigma). Medium was changed every 4 days and cell passaging was as described for iPSCs. 303 304
Caspase activity assay 305
Measurements of caspase activities in cells were performed using the commercially available Caspase-Glo 306 3/7 Assay (Promega, Madison, WI) according to the manufacturer's instructions. A previous experiment for 307 the determination of the cell density revealed an optimal linear range of the assay at 10.000 cells/well in a 308 96 well format. 309 310 Annexin V assay 311 iPSCs were seeded at a density of 1x10 5 cells/well onto a 24-well plate, and treated for 24h, 48h and 72h 312 with 1 µM of (-)-ILV or 0.1% DMSO and apoptotic cells were analyzed by using Annexin V FITC apoptosis 313 detection kit (Abcam). Following treatment, cells were washed with 500 µL Hank's Balanced Salt Solution 314 (HBSS, Gibco TM ) and dissociated as described above. Centrifugation was 400 rcf for 5 min and pellets 315 resuspended in a 100 μL 1x binding buffer. Further incubation was performed with 5 μL of FITC-conjugated 316 Annexin V and 5 μL of propidium iodide for 15 min in the dark. Prior to analysis, 200 μL of binding buffer was 317 added to each sample. Quantification was realized by flow cytometry and data analyzed using FlowJo 318 software. 319 320
Flow cytometry 321
For assessing cell surface antigens, 30 min staining on ice was carried out on fresh cells in cold FACS buffer 322 consisting of PBS, 10 μg/mL human IgG (Sigma), 1% FBS (Hyclone) and 0.01% sodium azide prior to fixation. 323
For intracellular antigens, staining was carried out on cells fixed with 4% paraformaldehyde (PFA) in PBS for 324 10 min and stored in methanol at -20°C for up to 4 weeks. Cells were stained at a density of 1x10 6 cells/mL 325 in a total of 100 μL FACS buffer with the appropriate antibody or isotype-matched control in a V-bottom 96-326 well plate. For two-colour staining, two antibodies or two isotype controls (attached to different 327 fluorophores) were added together. Following an incubation of 90 min at room temperature, cells were 328 washed three times with FACS buffer. When using unconjugated antibodies, a further incubation of 40 min, 329 at room temperature, was performed with a secondary antibody. Samples were washed another 3 times and 330 analysed using FACS Calibur flow cytometer (Becton Dickinson). Data were analysed using FlowJo software 331 and antibodies used are described in the Undirected differentiation 335 iPSC were washed with PBS and harvested by incubating the cells for 5 min at 37°C with 1 mL warm TrypLE 336 Express (Gibco TM ). The cells and TrypLE were well mixed into a single cell suspension by pipetting up and 337 down and collected in a 15 mL centrifuge tube and diluted 1∶10 with PBS. Cells were counted and spun down. 338
After centrifugation PBS was aspirated and the cell pellet was tapped loose and resuspended in mTeSR™-1 339 spin-EB medium consisting of mTeSR™-1 (Stem Cell Technologies), supplemented with 1 mM Rock-inhibitor 340 (Y27632, Calbiochem). For AggreWells TM 800 (Stemcell Technologies, 300 micro-wells), plates were first 341 prepared After preparing the plate, 1 mL of 4×10 6 PSC were added per well. The plate containing PSC and 2 342 mL of spin-EB medium per well was centrifuged at 800 rpm for 3 minutes. The plate was examined under the 343 microscope to verify cells were evenly distributed among the micro-wells. Very gently the plate was put into 344 the incubator and left for four days. The EBs were fed daily with spin-EB medium (first brought to RT), by gently aspirating 1 mL medium using a p1000 Gilson and very gently adding 1 mL fresh spin-EB medium in a 346 drop-wise manner down the side of the well so the EBs were not washed out of the microwells. This wash 347 was repeated to achieve a 75% medium change overall. To harvest EBs at day 4, the contents of the wells 348 were pipetted up and down several times using a 5 mL serological pipette to dislodge the EBs from the micro- iPSCs were seeded into an Aggrewell 800 well (STEMCELL Technologies) to form EBs, in mTeSR1 and fed daily 370 with medium plus 50 ng/mL BMP4 (Peprotech), 50 ng/mL VEGF (Peprotech), and 20 ng/mL SCF (Miltenyi 371 with 100 ng/mL M-CSF (Invitrogen), 25 ng/mL IL-3 (R&D), 2 mM Glutamax (Invitrogen), 100 U/mL penicillin 373 and 100 μg/mL streptomycin (Invitrogen), and 0.055 mM β-mercaptoethanol (Invitrogen), with fresh medium 374 added weekly. Macrophage precursors (pMacpre) emerging into the supernatant after approximately 375 1 month were collected weekly and differentiation cultures replenished with fresh medium. Harvested cells 376 were strained (40 μm, Corning) and plated onto tissue-culture treated plastic at 100,000 per cm 2 and 377 differentiated for 8 days to adherent macrophages (pMac) in X-VIVO15 with 100 ng/mL M-CSF, 2 mM 378 Glutamax, 100 units/mL penicillin-streptomycin. 379 380
Directed differentiation to cortical neuron progenitors 381
iPSCs were differentiated to cortical neuron progenitors (NPCs) iii with the following modifications: feeder-382 free iPSCs were plated onto Matrigel-coated 6-well plates, with neural induction for 12 days using dual SMAD 383 inhibition; after replating the neuroepithelial sheet on precoated wells with 20 µg/mL of laminin at day 12 384 using dispase II, 20 ng/mL fibroblast growth factor 2 (FGF2, R&D) was added to neural maintenance medium 385 (NMM) from days 12 to 15. Thereafter, a full medium change was performed every other day. On day 18, 386 newly formed rosettes were passaged either with dispase II or manually. For the latter, rectangles containing 387 rosettes were cut with a needle, and in case of large size, scored into multiple rectangles. The cell sheets 388 were then lifted manually, collected with a Gilson p200 and transferred in 2mL of NMM onto a new well 389 precoated with 20μg/mL laminin. Between day 18 and 25, a full medium change was performed every other 390 day, and cells were stained on day 25 for confocal imaging. 391 392 Immunocytochemistry 393
Undifferentiated iPSCs on Geltrex coated µ-slides were prepared for immunofluorescence microscopy as 394 followed. E-cadherin expression was monitored for cells seeded overnight prior to 24h treatment with 0.1% 395 DMSO, 1 µM ILV or 1 µM OXS8360. When looking at the expression of KI-67, Tra 1-60 or Nanog cells were 396 treated for 3 passages. Treated iPSCs were fixed with 4% PFA for 10 minutes at room temperature, 397 permeabilised and blocked with 10% goat serum and 0.3% Triton X-100 in PBS overnight at 4C prior to 398 washing 3 times with PBS and 0.3% Triton X-100. Anti-E-cadherin (2.5 µg/mL, clone 36, BD Transduction Laboratories or SHE78-7, Invitrogen), anti-KI-67 (1:400, Merck), anti-Tra-1-60 PE (conjugated, 1:10, 400 Biolegend), anti-Nanog Alexa Fluor 647 (conjugated, 1:10, Biolegend) antibodies were diluted in antibody 401 solution (PBS, 1% bovine serum albumin (BSA), 0.1% Triton X-100) and incubated overnight at 4C. When 402 using unconjugated antibodies, wells were washed prior to applying Alexa Fluor 647 (goat-anti-rabbit, IgG, 403 1:1000) diluted in antibody solution (PBS, 1% BSA, 0.3% Triton-X) for 2 hours at room temperature. 404
For cortical neuronal progenitors, pretreated cells with 0.1% DMSO or 1 µM OXS8360 were passaged on day 405 18 onto precoated µ-slides and grown until day 25. Cells were fixed with 4% PFA for 10 minutes at room 406 temperature, permeabilised and blocked with PBS, 1% donkey serum/1% goat serum, 0.3% Triton-X 407 overnight at 4C. Anti-PAX-6 (1:300, Covance) and anti-TUJ-1 (1:200, Covance) were used as primary 408 antibodies, and Alexa 488 (goat-anti-mouse, IgM, 1:1000) or Alexa Fluor 647 (goat-anti-rabbit, IgG, 1:1000) 409
were stained for visualization. 410
After washes, nuclei were counterstained with Hoechst 33342 or DAPI for 30 minutes at room temperature. 411 Fluorescent images were acquired using the FV1200 (Olympus) confocal microscope. All antibodies used are 412 described in the 
Enzyme-linked Immunosorbent Assay for soluble E-Cadherin 416
Cells were seeded in a 6-well plate at a density of 1 x 10 6 cells per well for 24 h prior to starting any treatment. 417
Medium was removed and a further incubation was realized in presence of 0.1% DMSO, 1 µM OXS8360 or 418 50 µM EDTA in fresh mTeSR TM . Medium from each condition was removed and E-cadherin concentrations 419 were quantified by using Human E-Cadherin Quantikine ELISA kit (Invitrogen). The Human E-Cadherin EIA kit 420 protocol was followed as described. Briefly, 100 μL of all sample or standard were added to appropriate wells 421 prior to incubating the microtiter plate for 2 h at 37°C. The sample solutions were removed and each well 422 was washed with 3 x 350 μL 1x Wash Buffer. Between each wash, the plate was emptied out and tapped 423 vigorously onto paper towel, especially after the last washing. 100 μL of Antibody-HRP Conjugate Solution 424 was added into each well followed by a 1 h incubation at 37°C. Sample solutions were removed and wells 425 were washed 4 times as described above. 100 μL of Substrate Solution were added into each wells followed 426 by a further incubation at 30°C for 30 min. 100 μL of Stop Solution was then added to each well before 427 recording the absorbance at OD = 450 nm. 428 429
Quantitative real-time PCR (qRT-PCR) 430
RNA extraction 431
RNA was either extracted from cell pellets that had previously been stored at -80°C, or from cell slurry. For 432 lysis, 350μL RLT buffer supplemented with 1% pure β-mercaptoethanol were added and the cell slurry was 433 transferred onto a QIAshredder spin column (Qiagen). Subsequently, cell lysates were spun on the 434 QIashredder column and RNA extracted using the RNeasy kit (Qiagen) according to the manufacturer's 435
protocol. An optional on-column DNase treatment for 15 minutes was performed. RNA yields were measured 436 by loading 1.5μL of extracted RNA onto the NanoDrop TM 2000c spectrophotometer. The optical density of 437 each sample was subsequently verified for its purity (A 260/280 ratio = 2). 438 cDNA production by reverse transcription (RT) Biosystems). Analysis of relative gene expression levels was performed according to the ΔΔCT approach vi . 457
Enzyme-linked Immunosorbent Assay for PKC activity 458
PKC activity was tested using PKC kinase activity assay (Abcam) according to the manufacturer's protocol. Buffer (blank) were also added in appropriate wells. The kinase reaction was initiated by adding 10 μl of ATP 466 to each well and the samples were incubated for 90 min at 30°C with gentle shaking after 20 min. The reaction 467 was stopped by removing the contents of each well. Samples, excluding blank ones, were incubated with 40 468 μl of Phosphospecific substrate antibody for 1 h at room temperature with gentle shaking every 20 min. Wells 469 were washed four times with Wash Buffer and then incubated with 40 μL of diluted anti-rabbit IgG-HRP 470 antibody for 30 min at room temperature, with gentle shaking every 10 min. Subsequently, all wells were 471 washed four times with Wash Buffer. In order to detect PKC activity, 60 μL of TMB substrate was added to 472 each well and the plate was incubated at room temperature for 60 min and then stopped by addition of 20 473 μL of Stop Solution. The PKC activity was analyzed by measuring the absorbance at OD = 450 nm. 
